Paratek Pharmaceuticals (PRTK): Analyst Day Takeaways - Baird

Baird analyst, Michael Ulz, reiterated his Outperform rating on shares of Paratek Pharmaceuticals (NASDAQ: PRTK) after an analyst day focused on omadacycline’s promising profile and encouraging value proposition.

Data from the OASIS study were highlighted along with notable updates from a number of Phase 1 studies that provided proof-of-principal in UTI and increased the analyst's confidence in CABP.

The analyst continues to believe omadacycline is underappreciated with what is expected to be a transformational 2017 (Phase 3 data from oral-only ABSSSI 2Q17 and CABP 3Q17).

No change to the price target of $40.

For an analyst ratings summary and ratings history on Paratek Pharmaceuticals click here. For more ratings news on Paratek Pharmaceuticals click here.

Shares of Paratek Pharmaceuticals closed at $13.00 yesterday.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
• Meta Platforms Inc. (META) PT Lowered to $480 at JPMorgan, 'Bigger AI Ambitions Drive Increasing Infrastructure Investments'